EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma

Roberto Chalela1,2,3,4*, Jose Gregorio González-García1,2,3, Karys Khilzi3, Victor Curull1,3,5, Albert Sánchez-Font1,3,4,5, Raquel Longarón6, Maria Teresa Rodrigo-Calvo6, Clara Martín-Ontiyuelo1,2,3, Joaquim Gea1,2,3,4†, and Beatríz Bellosillo1,7†

1Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain, 2Pompeu Fabra University, Barcelona, Spain, 3Respiratory Medicine Department, Hospital del Mar PSMAR, Barcelona, Spain, 4Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain, 5Autonomous University of Barcelona, Barcelona, Spain, 6Pathology Department, Hospital del Mar PSMAR, Barcelona, Spain, 7Pathology Department - Molecular Biology Laboratory, Hospital del Mar PSMAR, Barcelona, Spain

The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically “healthy cells”.

**Objective:** to demonstrate the presence of EGFR or KRAS mutations in non-tumoral lung cells in subjects with ADC and negative mutational status.

**Results:** mutations in EGFR or KRAS oncogenes were identified in the normal lung in 9.7% of the subjects. Exon 21 substitution L858R in EGFR was detected in two cases while the exon 19 deletion E746-A750 in the EGFR, the G12C and G12D substitutions in the KRAS were detected once. One patient presented three different mutations in the normal lung parenchyma (EGFR_L858R, KRAS_G12C and KRAS_G12D). The negative-mutation status of the tumor and the mutations detected in the “normal lung” were confirmed using highly sensitive and specific TaqMan PCR (CAST-PCR). No differences were found in terms of progression, progression-free survival or overall survival during the 18 months follow-up.

**Conclusions:** These results confirm the presence of driver mutations in the histologically normal lung parenchyma cells in the absence of mutations coexisting with the primary tumor.

**Keywords:** adenocarcinoma lung, driver mutation, EGFR-epidermal growth factor receptor, KRAS, Prognosis

**INTRODUCTION**

Lung cancer, specifically lung adenocarcinoma (ADC), is frequently diagnosed in an advanced stage with a global 5-years survival not exceeding 17% [1–3]. Even when it is detected at an early stage, the prognosis is poor, especially in terms of tumor recurrence [4, 5]. Pulmonary ADC has an extraordinarily high mutational burden and somatic genomic alterations can be found in more
than 75% of the cases. Fortunately, a vast proportion of the oncogenic driver alterations has potential therapeutic implications [6]. The acquisition of driver mutations in still histologically non-tumoral cells appears to be very important during the ADC carcinogenesis since it will potentially lead to a clonal cell expansion [7]. Moreover, two studies have demonstrated the presence of cancer-related mutations in non-tumoral cells of subjects with endometriosis and arteriovenous malformations of the brain [8, 9]. These findings demonstrate that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically non-tumoral cells. Our group has recently demonstrated that subjects with localized lung ADC with epidermal growth factor receptor-EGFR or KRAS proto-oncogene alterations showed the same driver mutation in the non-tumoral lung tissue as far as a 21.3% of the cases [9]. These findings were associated with a significantly lower disease-free survival at 12 months and are in line with other previously published evidence related with molecular alterations in non-tumoral lung [10]. Our hypothesis is that cancer-related mutations can appear in histologically non-cancerous cells even in the absence of molecular alterations in the primary tumor during the field carcinization process. Accordingly, the aim of the present study was to demonstrate the presence of EGFR or KRAS mutations in non-tumoral lung cells even in subjects with early-stage ADC with negative mutational testing.

METHODS

Subjects

Subjects with early-stage lung ADC with negative mutational status and candidates for curative surgical resection were prospectively recruited in our center, a tertiary teaching hospital. Tumor and histologically normal lung parenchyma samples were obtained and processed. Thirty-five subjects with EGFR mutation-negative and KRAS mutation-negative lung adenocarcinoma were included. The normal lung parenchyma (NLP) sample was defined as a histologically normal tissue with complete absence of micro-tumor invasion assessed by a pathologist and obtained in the area of the resected lung furthest from the tumor. Finally, viable non-tumoral DNA was obtained in 31 of these subjects and a competitive allele-specific TaqMan PCR was performed to identify the presence of EGFR or KRAS mutations. The cohort was followed-up during 18 months and clinical data were collected for months 1, 2, 6, 12 and 18. The study was designed and carried out in accordance with the ethical guidelines of the Declaration of Helsinki and European legislation, and the procedure was approved by our Ethics Committee. Informed consent was obtained from all individuals.

Tumor DNA Extraction and Sequencing

The molecular study of the tumor was carried out after surgery and included the detection of EGFR using TheraScreen PCR and direct sequencing for KRAS alterations. The commercially kit QIAamp DNA Mini kit (Qiagen, Hilden, Germany) was used for DNA extraction. The EGFR mutations were detected using the commercial real-time PCR TheraScreen EGFR RGQ PCR kit (Qiagen). This is a highly sensitive assay based on Scorpions® real-time PCR technology and mutation specific ARMS® primers that detect 29 different somatic mutations in the gene. In addition, exon 2 of the KRAS gene and exons 18, 19, 20, 21 of the EGFR gene were studied with Sanger sequencing, using BigDye v3.1 (Applied Biosystems, Foster City, CA, United States), being assessed on the 3500DX Genetic Analyzer (Applied Biosystems).

Normal Lung Parenchyma DNA Extraction and Sequencing

DNA was extracted from two sections of normal appearing lung samples using the QIAamp DNA Mini kit (Qiagen). Competitive allele-specific TaqMan PCR (CAST-PCR, Applied Biosystems, 4465804) was performed in order to determine KRAS and EGFR mutational status. Samples were amplified in duplicate in independent experiments with TaqMan™ Genotyping Master Mix (ThermoFisher) using the following assays: KRAS p.G12C—Hs00000113_mu; KRAS p.G12V—Hs00000119_mu; KRAS p.G12D—Hs00000121_mu; KRAS p.G12A—Hs00000123_mu; KRAS p.G12R—Hs00000117_mu; and KRAS p.G13C—Hs00000125_mu, EGFR exon 19 deletions—Hs00000228_mu; EGFR p.L858R—Hs00000102_mu; EGFR p.T790M—Hs00000106_mu and G719A—Hs00000104_mu. PCR amplifications were performed in a 7500Fast real-time PCR system (Applied Biosystems). All experiments have been confirmed and the technique complies with the Minimum Information for Publication of Quantitative Real-time PCR Experiments (MIQE).

Statistical Analysis

Categorical variables were described as frequencies and percentages, whereas continuous variables as mean ± standard deviation. Pearson’s Chi-Square or Fisher exact tests were used to compare categorical variables. The non-parametric Mann-Whitney U test was used to assess differences between groups. p values ≤0.05 were considered statistically significant. Analyses were performed with SPSS 21.0.

RESULTS

The main clinical, functional and tumor characteristics of the cohort are shown in Table 1. All subjects were stratified in stages based on the present TNM classification (IASLC, 8th edition) and only stage I or II subjects were included [3]. The surgical procedures were performed in accordance with the institution clinical-practice recommendations. The most common procedure was a lobectomy (67.7%) followed by segmentectomy (22.6%) and bilobectomy (9.7%). Almost all the subjects (30 of 31, 96.8%) were smokers or former smokers.

We identified five mutations in EGFR or KRAS oncogenes in the normal lung parenchyma among three subjects (9.7%). The exon 21 substitution L858R in EGFR was detected in two cases while the exon 19 deletion E746-A750 in the EGFR, the codon 12
substitution G12C and G12D in the KRAS were detected once. Surprisingly, in one patient, three different mutations were identified in NLP (EGFR_L858R, KRAS_G12C and KRAS_G12D). More details of the three subjects with mutated NLP can be found in Table 2.

In these three subjects, the negative-mutation status of the tumor for the specific mutation detected in the NLP was confirmed using highly sensitive and specific TaqMan PCR (CAST-PCR). The confirmation of the positive-mutation status in the NLP was also performed for the previously mentioned five specific mutations. In all the assays, the PCR efficiency was between 95 and 105%. To improve specificity and avoid false positives we only considered as positives the assays for EGFR mutations when the amplification occurred before the cycle 35. For the two KRAS mutations detected, the amplification occurred between the cycle 35 and 38. The mutation was confirmed in both cases. The amplification plots are shown in Figure 1. Real-time PCR results for positive cases were confirmed in independent experiments. We have also performed digital PCR (dPCR) to confirm the presence of the mutations reported and, in addition, with the samples with enough material, we have repeated the qPCR assays.

**Mutated NLP vs. Non-mutated NLP: Clinical Outcomes, Recurrence and Survival**

We only found differences between both groups in terms of tobacco status and gender, but considering the limited number of cases, we cannot draw any conclusion. Data from both groups are shown in Table 1.

One patient died in the post-operative setting. During the 18 months follow-up, two subjects died within the non-mutated NLP group, while none died in the other group. No differences were found in terms of progression (locally or at distance), progression-free survival or overall survival between both groups during the follow-up.

**DISCUSSION**

This study confirms the presence of driver mutations in the histologically normal lung parenchyma cells coexisting with the absence of mutations in the primary tumor. Our findings are consistent with the hypothesis that during the carcinogenesis process multiple cells can gain somatic mutations without

| TABLE 1 | Baseline characteristics and comparison between mutated NLP and non-mutated NLP. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Total n = 31** | **Mutated NLP n = 3** | **Non-mutated NLP n = 28** | **p value** |
| Age, mean (SD), yrs | 64.2 (7.2) | 60 (6) | 64.5 (7.1) | 0.29 |
| Current or former smoker, n (%) | 30 (96.8) | 2 (66.7) | 28 (100) | 0.00 |
| Smoking index, mean (SD), pack-year | 53.2 (23) | 40 (34.6) | 54.6 (22) | 0.30 |
| Sex, n (%) | | | | |
| Male | 25 (81) | 1 (33) | 24 (86) | 0.02 |
| Female | 6 (19) | 2 (67) | 4 (14) | |
| Comorbidities, n (%) | | | | |
| Previous cancer | 12 (38.7) | 1 (33.3) | 11 (39.3) | 0.84 |
| Dyslipidemia | 10 (32.3) | 1 (33.3) | 9 (32.1) | 0.96 |
| Hypertension | 10 (32.3) | 0 (0) | 10 (35.7) | 0.20 |
| Diabetes mellitus | 7 (22.6) | 1 (33.3) | 6 (21.4) | 0.63 |
| Alcoholism | 9 (29) | 0 (0) | 9 (32.1) | 0.24 |
| COPD | 8 (25.8) | 0 (0) | 8 (28.6) | 0.28 |
| Ischemic cardiomyopathy | 2 (6.5) | 0 (0) | 2 (7.1) | 0.63 |
| Chronic kidney disease | 1 (3.2) | 0 (0) | 1 (3.6) | 0.73 |
| Lung function tests, mean (SD) | | | | |
| FEV1, % ref | 74.5 (16.1) | 81 (31.1) | 74.2 (15.3) | 0.56 |
| FVC, % ref | 86.9 (16.6) | 85.5 (28.9) | 86.5 (16.1) | 0.93 |
| TLC, % ref | 99.9 (13) | 77 | 99.8 (13) | 0.09 |
| RV/TLC, % | 46.2 (11) | 38 | 46.2 (11) | 0.47 |
| DLCO, % ref | 65.3 (18.8) | 79.5 (47) | 64.4 (16.4) | 0.27 |
| Karnofsky scale, mean (SD) | 93.3 (6) | 100 | 92.8 (8) | 0.09 |
| Tumor characteristics | | | | |
| SUV By PET, mean (SD), cm | 6.5 (4.7) | 3.4 (2.5) | 6.8 (4.7) | 0.33 |
| T (tumor size), mean (SD), cm | 2.8 (18.4) | 1.4 (0.1) | 2.9 (1.8) | 0.15 |
| N (nodal infiltration), n (%) | 3 (9.7) | 1 (33.3) | 2 (7.1) | 0.14 |
| M (metastasis), n (%) | 0 (0) | 0 (0) | 0 (0) | — |
| Post-operative stage groups, n (%) | | | | |
| I | 23 (74.2) | 21 (75) | 2 (66.7) | 0.75 |
| II | 8 (25.8) | 1 (33.3) | 7 (25) | 0.75 |
| III - IV | 0 (0) | 0 (0) | 0 (0) | — |
| Diagnostic tests, n (%) | | | | |
| PET-CT scan | 27 (87.1) | 2 (66.7) | 25 (89.2) | 0.77 |
| Endobronchial ultrasound (EBUS) | 17 (54.8) | 2 (66.7) | 15 (53.6) | 0.76 |

Abbreviations: NLP, normal lung parenchyma; SD, standard deviation; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; DLco, transfer coefficient for CO; SUV, standardized uptake value; PET, positron emission tomography.
| N° | Age (years) | Sex | TNM | Mutational status in NLP | Distant - local progression | Site of progression |
|----|-------------|-----|-----|--------------------------|-----------------------------|--------------------|
| 1  | 69          | M   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 2  | 67          | M   | T3N1M0  | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 3  | 56          | M   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | YES Adrenal       |
| 4  | 55          | M   | T1BN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 5  | 62          | M   | T2AN1M0 | KRAS Wild-type                 | EGFR Wild-type                   | YES Lymph Nodes Local progression |
| 6  | 58          | M   | T1BN0M0 | KRAS Wild-type                 | NO                            | Adrenal           |
| 7  | 59          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | YES Brain         |
| 8  | 67          | M   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 9  | 55          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 10 | 67          | M   | T1BN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 11 | 55          | M   | T3N0M0  | KRAS Wild-type                 | EGFR Wild-type                   | YES Local progression |
| 12 | 69          | M   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 13 | 78          | M   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 14 | 75          | M   | T1BN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | YES Lymph Nodes Bones |
| 15 | 73          | M   | T3N0M0  | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 16 | 66          | M   | T1BN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 17 | 53          | F   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 18 | 60          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 19 | 60          | F   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 20 | 59          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 21 | 53          | M   | T1AN0M0 | EGFR deletion E746_A750       | NO                            | EGFR substitution L858R |
| 22 | 64          | F   | T1AN0M0 | KRAS Wild-type                 | KRAS Gly12Cys                   | YES Liver         |
| 23 | 63          | F   | T1BN0M0 | KRAS Wild-type                 | KRAS Gly12Cys                   | NO                |
| 24 | 72          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 25 | 68          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 26 | 61          | F   | T1BN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 27 | 70          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | NO                |
| 28 | 67          | M   | T1AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | YES Lymph Nodes   |
| 29 | 80          | M   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | YES Adrenal       |
| 30 | 65          | M   | T2AN0M0 | KRAS Wild-type                 | EGFR Wild-type                   | YES Brain         |
| 31 | 63          | F   | T1AN0M0 | EGFR Wild-type                 | KRAS Wild-type                   | NO                |

Abbreviations: EGFR, Epidermal Growth Factor Receptor gene; KRAS, Kirsten Rat Sarcoma viral oncogene homolog.
necessarily producing a clonal expansion. In a previous study, we confirmed that the same driver mutation detected in the lung adenocarcinoma was also present in non-tumoral samples in a fifth of the subjects. However, this study has the limitation that this detection could be secondary to contamination by tumor DNA from blood or tumor cells, which may not have been detected by the usual histopathological methods. Although this limitation was unlikely, it could not be one hundred percent ruled out. In the present study, having excluded the presence of mutations in EGFR or KRAS by highly specific and sensitive techniques in the primary tumor, we are able to confirm that the mutations detected in other lung cells were not the result of contamination from the tumor. These findings make us change the way we understand and define a driver-mutation.

The prevalence of EGFR and KRAS mutations detected in the present study is only 9.7%, lower than the one detected in our previous study (21.3%) and in those studies on endometriosis (26%) and arteriovenous malformations of the brain (48%). The prevalence observed in the present study is likely to be higher if more extensive molecular studies that included other molecular alterations were carried out. Additionally, to stress our ambitious hypothesis, we decided to increase the specificity not including the mutations occurred in later cycles of PCR as well as to exclude the substitution of T790M in exon 20 that are usually considered as secondary mutations in the final analysis.

In the present study, we could not find differences in clinical outcomes such as recurrence or disease-free survival, between the two groups, possibly because of the sample size. One patient (33.3%) in the group of the mutated NLP presented progression at 18 months in the form of hepatic metastases; while in the non-mutated NLP group 8 (28.6%) did, not reaching however statistical significance. Subjects in the mutated NLP group were significantly less-frequent smokers and predominantly
women when compared with the non-mutated NLP group, this is in line with evidence that is consistent with the higher prevalence of driver-mutations in non-smoker women.

Interestingly, one patient presented three different mutations in the NLP sample which included one in the EGFR and two in the KRAS. Normally the mutations in EGFR and KRAS are considered as mutually exclusive mutations in lung cancer. Although this finding is surprising, it does not seem improbable either, since, unlike a tumor, where all the cells come from the clonal expansion of a single malignant cell, the normal lung parenchyma samples may contain multiple different cell lines. Our results support our prior hypothesis that molecular changes can occur in multiple cells even without malignancy changes.

LIMITATIONS

There are multiple limitations in the present study, mainly the small sample size, although this limitation does not affect the main objective of the study, which was to demonstrate the presence of driver-mutations in the absence of tumor mutations. The sample size surely affects clinical outcomes, which was not the objective of the study. Contamination or sample mix-up of the studied samples with tumor cells that contain molecular alterations has always been a topic of discussion, but we consider it highly unlikely for several reasons. First, by ruling out molecular alterations in the sample mix-up of the studied samples with tumor cells that contain molecular alterations has always been a topic of discussion, but we consider it highly unlikely for several reasons. First, by ruling out molecular alterations in the tumor, contamination would be much less relevant. Second, a “non-tumoral lung” sample was considered when resection margins were tumor-free assessed by an expert pathologist and the area of lung farthest from the tumor was selected for the molecular analysis.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer J Clinicians (2016). 66:7–30. doi:10.3322/caac.21332
2. American Cancer Society. Cancer facts & figures 2016. Atlanta: American Cancer Society (2016).
3. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol (2016). 11:39–51. doi:10.1016/j.jtho.2015.09.009
4. Nakagawa T, Okumura T, Matsuoka T, Kameyama K. Postrecurrence survival in patients with stage I non-small cell lung cancer. Eur J Cardio-Thoracic Surg (2008). 34:499–504. doi:10.1016/j.ejcts.2008.05.016
5. Martini N, Bains MS, Burt ME, Zalouek MF, McCormack P, Ruch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg (1995). 109:120–9. doi:10.1016/0022-5223(95)70427-2
6. Chalela R, Currull V, Enríquez C, Pijuan L, Bellosillo B, Góz J. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. J Thorac Dis (2017). 9:2142–58. doi:10.21037/jtd.2017.06.20

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Comité de Ética de la Investigación con Medicamentos CEIm-PSMAR. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

RC: Design and methodology, acquisition of funding, data collection, laboratory sample processing, data analysis and writing. JGG-G: Data collection and data analysis. KK: Data collection and data analysis. VC: Design, expertise, feedback, acquisition of funding and writing. AS-F: Expertise, data collection and feedback. RL: Laboratory sample processing. MTR-C: Laboratory sample processing and pathology analysis. CM-O: Data analysis and feedback. JG: Design, expertise, feedback, acquisition of funding and writing. BB: Design, expertise, feedback, acquisition of funding and writing.

FUNDING

This study have been funded by Fundació La Marató TV3—201305-30; FUCAPI 2015; SEPAR 2015 (Project and; Fellowship); SGR 2014SGR424; SGR2017205 and CIBERES (ISCIII).

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

ACKNOWLEDGMENTS

To Daniel Pertuz for his editing aid.

7. Stratton MB, Campbell PJ, Futreal PA. The cancer genome. Nature (2009). 458(7239):719–24. doi:10.1038/nature07943
8. Angelisio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noé M, Horlings HM, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med (2017). 376(19):1835–48. doi:10.1056/nejmoa1614814
9. Nikolaeff SL, Vetiska S, Bonilla X, Boudreau E, Jauhiainen S, Rezai Jahromi B, et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med (2018). 378(3):250–61. doi:10.1056/nejmoa1709449
10. Chalela R, Bellosillo B, Currull V, Longarón R, Pascual-Guardia S, Badenes-Bonet D, et al. EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma. Jcm (2019). 8(4):529. doi:10.3390/jcm8040529

Copyright © 2021 Chalela, González-García, Khiltiz, Currull, Sánchez-Font, Longarón, Rodrigo-Calvo, Martín-Ontinyent, Góz and Bellosillo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.